---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-071764"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:04:25.245015+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal to begin tecarfarin trial in ESKD patients transitioning to dialysis later this year

## Summary
- Trial includes ESKD patients with and without atrial fibrillation, enrollment planned to begin later this year.
- Tecarfarin has orphan drug and fast-track designations for ESKD+AFib, highlighting unmet need.
- Addresses critical gap: no proven anticoagulant for dialysis initiation period, which carries excess cardiovascular risk.
- CEO Quang X. Pham calls the study an important step forward for tecarfarin development.

## SEC filing metadata
- accession: 0001213900-25-071764
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025071764/0001213900-25-071764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025071764/ea0251809-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-071764
- JSON: https://secwatch.observer/filing/0001213900-25-071764.json
- Plain text: https://secwatch.observer/filing/0001213900-25-071764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.